<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161259">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01668095</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000738499</org_study_id>
    <secondary_id>COG-ARST12B8</secondary_id>
    <nct_id>NCT01668095</nct_id>
  </id_info>
  <brief_title>Biomarkers in Patients With Advanced Rhabdomyosarcoma</brief_title>
  <official_title>Developmental Pathway Drug-Targets in Advanced Rhabdomyosarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may
      help doctors identify biomarkers related to cancer.

      PURPOSE: This clinical trial studies tumor tissue from patients with rhabdomyosarcoma to
      identify important proteins and biomarkers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To investigate whether the expression of a subset of proteins (by
           immunohistochemistry), known to be involved in the Pax3, Pax7, and Patched-1
           neuromuscular development pathways, are dysregulated in advanced and relapsed alveolar
           and embryonal rhabdomyosarcomas.

      OUTLINE: Iimmunohistochemistry is performed for each candidate target (Pax3, Pax7, and
      Patched-1) in each disease (alveolar, embryonal, and anaplastic rhabdomyosarcoma) for tissue
      microarray analysis.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2012</start_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>N/A</study_design>
  <primary_outcome>
    <measure>Prevalence of the candidate target (Pax3, Pax7, or Patched-1), and whether the candidate target is expressed in the tumor vs stroma</measure>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>microarray analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  8 tissue microarrays (TMA) slides of the following diseases available:

               -  Alveolar rhabdomyosarcoma

               -  Embryonal rhabdomyosarcoma

               -  Anaplastic rhabdomyosarcoma

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  Not specified
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Keller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <link>
    <url>http://cancer.gov/clinicaltrials/COG-ARST12B8</url>
    <description>Clinical trial summary from the National Cancer Institute's PDQÂ® database</description>
  </link>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 18, 2012</lastchanged_date>
  <firstreceived_date>August 15, 2012</firstreceived_date>
  <responsible_party>
    <name_title>Peter C. Adamson</name_title>
    <organization>Children's Oncology Group - Group Chair Office</organization>
  </responsible_party>
  <keyword>adult rhabdomyosarcoma</keyword>
  <keyword>alveolar childhood rhabdomyosarcoma</keyword>
  <keyword>embryonal childhood rhabdomyosarcoma</keyword>
  <keyword>previously treated childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent adult soft tissue sarcoma</keyword>
  <keyword>recurrent childhood rhabdomyosarcoma</keyword>
  <keyword>stage III adult soft tissue sarcoma</keyword>
  <keyword>stage IV adult soft tissue sarcoma</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rhabdomyosarcoma</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
